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Sa multinational study that assessed the effectiveness of DA using the SilverHawkTM
and TurboHawkTMPlaque ExcisionSystems (Covidien/ev3, Plymouth, MN) for
treatment of peripheral arterial disease.
Methods: The DEFINITIVE LE study enrolled 800 patients. Of those, 70 had CLI
and at least one infrapopliteal target lesion treated with DA. Endpoints and adverse
events were assessed by independent core laboratories and a Clinical Events
Committee. The primary endpoint for the CLI cohort was freedom from major
unplanned amputation of the target limb at 12 months.
Results: Within the DEFINITIVE LE study, 70 patients with CLI had 96 infrapo-
pliteal target lesions treated with DA. The breakdown by Rutherford Clinical Category
(RCC) was as follows: RCC 4: 34%, RCC 5: 63%, and RCC 6: 3%.The mean age
was74 years, 56% were male and79% had diabetes.The mean lesion length was 6.0
cm and the mean baseline stenosis was 77%. One-third (33%) of lesions were
occluded,31% of lesions were calciﬁed and 39% had inﬂow disease treated during the
same procedure.Periprocedural complications included 1 (1%) perforation and 3 (4%)
embolizations; there were no ﬂow-limiting dissections. At 12 months, limb salvage
was 94%, primary patency was 78% and freedom from target lesion revascularization
(TLR) was 87%, per Kaplan-Meier estimates. Complete wound healing at 12 months
was 68%.
Conclusions: This prospective assessment of DA for treatment of Infrapopliteal
lesions in CLI patients showed low complication rates and high rates of limb salva-
ge,freedom from TLR, and primary patency at 12 months comparable to recent drug
eluting stent trials. These ﬁndings should be taken into consideration when treating
this challenging group of patients.
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Background: The natural history of patients with intermittent claudication (IC) has
been reported. However, little is known about prognosis of claudicant patients after
endvascular therapy (EVT).
Methods: This study was performed as a large-scale multicenter, retrospective
registry. A total of 2,930 consecutive patients (mean age, 71.58.9 years, 78.7%
male) with IC treated by EVT for a de novo ilio-femoral lesion were enrolled. The
primary outcome measure was overall survival, and the secondary outcome measure
were freedom from major adverse cardiovascular events (MACE; all-cause death
(ACD), myocardial infarction and stroke), and major adverse cardiovascular and limb
events (MACLE; any repeat revascularization for limb and leg amputation in addition
to MACE).
Results: The overall survival rate was 97.2%, 90.8%, and 83.4% at 1, 3 and 5 years.
The cause of death was cardiovascular in 42.8%. Freedom from MACE (MACLE)
was 96.7% (84.5%), 88.6% (68.1%), and 77.3% (58.7%) at 1, 3and 5 years. On
multivariate analysis performed logistic regression by prespeciﬁed risk factors,
elderly age, Dialysis, LV dysfunction, Insulin administration, complication of
hematoma, Coronary artery disease, SFA plus iliac lesions were found to be positive
independent predictors of ACD. ACEI/ARB, Ca-antagonist administration were
negative predictor. Risk stratiﬁcation of ACD based on these seven positive
predictors. Elderly age, Dialysis, LV dysfunction, Insulin administration and
complication of hematoma were scored as 2 points. The others were assigned 1 point
each. The scores of 0 to 2, 3 to 5, and >6 points were classiﬁed as low-, moderate-
and high-risk patients, respectively. The overall survival rate was signiﬁcantly lower
in the high-risk patients than other two groups (90.1% vs. 78.6% vs. 53.5% at 5years,
P<0.0001; log-rank test).
Conclusions: The prognosis after EVT for patients with IC was relative good.
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Background: The EGO-COMBO study is the ﬁrst study ever designed to establish
the healing proﬁle of a DES, and beneﬁts of the dual therapy COMBO Stent
(OrbusNeich, US), a hybrid version of the EPC-capturing Genous Stent plus a 5mg/
mm abluminal sirolimus coating, using sequential OCT FUs to 24 months.
Methods: In this prospective single center study, 61 patients (9M DAPT) received 3
longitudinal sequential OCTs at baseline (for optimal stent apposition), at early FU (4
monthly group 2nd to 5th month, in 1:2:2:1 ratio, for % strut coverage using 6
Categories), then at 9M (for late loss and OCT neointima), and clinical FU to 12M.
With a 2nd approved protocol, a 24M OCT FU was initiated for long term outcomes.
All clinical event adjudication, QCA & OCT analyses were undertaken by CRF Core
Lab., NY.
Results: 61 patients (33% DM) received 88 COMBO stents (size 3.060.39mm &
length 23.97.62mm). Early strut coverage (OCT Cat. D to F) increased from 84.3,
90.2, 90.5, to 92%; interpolated 100% coverage at 150 days. 9M OCT FU Rate was
100%; only 1 TLR treated by POBA (MACE Rate 1/61 ¼ 1.64%). 9M late loss was
0.240.36mm, OCT NIT 0.157mm & NIA 1.445mm2. At 24M, 1 case lost to FU
(migrated to China), another elderly patient died from VF after days of recurrent chest
pain without seeking advice. All remaining 59 cases were entirely asymptomatic & 18
declined the 4th OCT FU (24M Clinical FU Rate 58/59 ¼ 98.3% & OCT FU Rate 40/
58 ¼ 69.0%). To date, 39 patients have had the restudy, all showing excellent results
(late loss catch up <0.1mm; OCT NIT D 0.002mm; NIA D 0.13mm2), without
neoatherosclerosis or late stent thrombosis (not even micro-thrombi by OCT). Thus,
24M MACE Rate 2/61 ¼ 3.28%; ﬁnal core lab. results pending.
Conclusions: Using stringent longitudinal sequential OCT FUs with core lab. adju-
dication, the dual therapy COMBO stent is the ﬁrst DES ever with a healing proﬁle
established and appears to be a novel device (excellent healing with optimal neo-
intimal suppression without late stent thrombosis) with durable 24M outcomes. This
longitudinal sequential OCT FU approach may be adopted to guide development of
any new stent platform, appropriate DAPT duration, and to predict (prevent) late stent
thrombosis.
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Background: Whether IVUS guidance reduces the long-term rates of stent throm-
bosis (ST) after drug-eluting stent (DES) implantation is controversial.acts/ORAL/Invasive Imaging B21
